6.
Scott J, Sharma R, Meredith L, Dunning J, Moore C, Sahr F
. Pharmacokinetics of TKM-130803 in Sierra Leonean patients with Ebola virus disease: plasma concentrations exceed target levels, with drug accumulation in the most severe patients. EBioMedicine. 2020; 52:102601.
PMC: 7033524.
DOI: 10.1016/j.ebiom.2019.102601.
View
7.
Liu X, Pappas E, Husby M, Motsa B, Stahelin R, Pienaar E
. Mechanisms of phosphatidylserine influence on viral production: A computational model of Ebola virus matrix protein assembly. J Biol Chem. 2022; 298(7):102025.
PMC: 9218153.
DOI: 10.1016/j.jbc.2022.102025.
View
8.
Kirchdoerfer R, Moyer C, Abelson D, Saphire E
. The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis. PLoS Pathog. 2016; 12(10):e1005937.
PMC: 5068707.
DOI: 10.1371/journal.ppat.1005937.
View
9.
Landeras-Bueno S, Oda S, Norris M, Salie Z, Guenaga J, Wyatt R
. Sudan Ebolavirus VP35-NP Crystal Structure Reveals a Potential Target for Pan-Filovirus Treatment. mBio. 2019; 10(4).
PMC: 6650547.
DOI: 10.1128/mBio.00734-19.
View
10.
Johnson R, Bell P, Harty R
. Effect of Ebola virus proteins GP, NP and VP35 on VP40 VLP morphology. Virol J. 2006; 3:31.
PMC: 1502131.
DOI: 10.1186/1743-422X-3-31.
View
11.
Hoenen T, Shabman R, Groseth A, Herwig A, Weber M, Schudt G
. Inclusion bodies are a site of ebolavirus replication. J Virol. 2012; 86(21):11779-88.
PMC: 3486333.
DOI: 10.1128/JVI.01525-12.
View
12.
Bosworth A, Dowall S, Garcia-Dorival I, Rickett N, Bruce C, Matthews D
. A comparison of host gene expression signatures associated with infection in vitro by the Makona and Ecran (Mayinga) variants of Ebola virus. Sci Rep. 2017; 7:43144.
PMC: 5327407.
DOI: 10.1038/srep43144.
View
13.
Dong S, Yang P, Li G, Liu B, Wang W, Liu X
. Insight into the Ebola virus nucleocapsid assembly mechanism: crystal structure of Ebola virus nucleoprotein core domain at 1.8 Å resolution. Protein Cell. 2015; 6(5):351-62.
PMC: 4417675.
DOI: 10.1007/s13238-015-0163-3.
View
14.
ELLIOTT L, Kiley M, McCormick J
. Descriptive analysis of Ebola virus proteins. Virology. 1985; 147(1):169-76.
DOI: 10.1016/0042-6822(85)90236-3.
View
15.
Wu L, Jin D, Wang D, Jing X, Gong P, Qin Y
. The two-stage interaction of Ebola virus VP40 with nucleoprotein results in a switch from viral RNA synthesis to virion assembly/budding. Protein Cell. 2020; 13(2):120-140.
PMC: 8783937.
DOI: 10.1007/s13238-020-00764-0.
View
16.
Noda T, Hagiwara K, Sagara H, Kawaoka Y
. Characterization of the Ebola virus nucleoprotein-RNA complex. J Gen Virol. 2010; 91(Pt 6):1478-83.
PMC: 2878588.
DOI: 10.1099/vir.0.019794-0.
View
17.
Adu-Gyamfi E, Soni S, Xue Y, Digman M, Gratton E, Stahelin R
. The Ebola virus matrix protein penetrates into the plasma membrane: a key step in viral protein 40 (VP40) oligomerization and viral egress. J Biol Chem. 2013; 288(8):5779-89.
PMC: 3581432.
DOI: 10.1074/jbc.M112.443960.
View
18.
Albarino C, Wiggleton Guerrero L, Chakrabarti A, Nichol S
. Transcriptional analysis of viral mRNAs reveals common transcription patterns in cells infected by five different filoviruses. PLoS One. 2018; 13(8):e0201827.
PMC: 6072132.
DOI: 10.1371/journal.pone.0201827.
View
19.
Dunning J, Sahr F, Rojek A, Gannon F, Carson G, Idriss B
. Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLoS Med. 2016; 13(4):e1001997.
PMC: 4836798.
DOI: 10.1371/journal.pmed.1001997.
View
20.
Licata J, Johnson R, Han Z, Harty R
. Contribution of ebola virus glycoprotein, nucleoprotein, and VP24 to budding of VP40 virus-like particles. J Virol. 2004; 78(14):7344-51.
PMC: 434112.
DOI: 10.1128/JVI.78.14.7344-7351.2004.
View